Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference | ATHE Stock NewsStockTitan·Oct 9, 2026 at 03:05 AMATHE+1.47%
Alterity Therapeutics Sets 2026 AGM Date and Director Nomination DeadlineTip Ranks·Sep 25, 2026 at 03:57 AMATHE+1.47%
Insider Move at Biotech Firm Sparks Fresh Investor InterestTip Ranks·Sep 9, 2026 at 02:08 AMATHE+1.47%
Alterity Therapeutics director Peter Ashley Marks acquires 47,620 shares for $0.50 each, valued at $23,810PUBT·Sep 8, 2026 at 11:02 PMATHE+1.47%
Alterity Therapeutics Issues 8.4 Million Shares Under Underwriting DealTip Ranks·Sep 8, 2026 at 02:07 AMATHE+1.47%
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 | ATHE Stock NewsStockTitan·Sep 3, 2026 at 03:05 AMATHE+1.47%
Alterity Therapeutics issues shares from exercise of listed options at A$0.5 eachPUBT·Aug 31, 2026 at 10:58 AMATHE+1.47%
Alterity Therapeutics FY26 net loss widens to $23.4 million; R&D expenses rise 22% to A$17.63 millionPUBT·Aug 28, 2026 at 01:16 PMATHE+1.47%
